Literature DB >> 9378726

Midkine, a retinoic acid-inducible heparin-binding cytokine in inflammatory responses: chemotactic activity to neutrophils and association with inflammatory synovitis.

T Takada1, K Toriyama, H Muramatsu, X J Song, S Torii, T Muramatsu.   

Abstract

Midkine (MK) is a retinoic acid-inducible heparin-binding cytokine. In the inflammatory synovitis of rheumatoid arthritis and osteoarthritis, MK was detected in synovial fluid, synoviocytes, and endothelial cells of new blood vessels. Normal synovial fluid and noninflammatory synovial tissue did not contain detectable MK. Therefore, MK showed inflammation-associated expression in these cases. Furthermore, MK was found to promote chemotaxis of neutrophils in the range of 10 ng/ml. The mode of action of MK was found to be haptotactic; the substrate-bound form of MK was the active one. MK is also known to promote fibrinolysis. These activities of MK are in agreement with the modes of MK expression in various pathological statuses, and thus MK is proposed to be an important molecule regulating inflammatory responses.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9378726     DOI: 10.1093/oxfordjournals.jbchem.a021773

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  43 in total

1.  Nuclear targeting by the growth factor midkine.

Authors:  Yoshihisa Shibata; Takashi Muramatsu; Makoto Hirai; Tatsuya Inui; Terutoshi Kimura; Hidehiko Saito; Lynn M McCormick; Guojun Bu; Kenji Kadomatsu
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

2.  Midkine and pleiotrophin have bactericidal properties: preserved antibacterial activity in a family of heparin-binding growth factors during evolution.

Authors:  Sara L Svensson; Mukesh Pasupuleti; Björn Walse; Martin Malmsten; Matthias Mörgelin; Camilla Sjögren; Anders I Olin; Mattias Collin; Artur Schmidtchen; Ruth Palmer; Arne Egesten
Journal:  J Biol Chem       Date:  2010-03-22       Impact factor: 5.157

Review 3.  Structure and function of midkine as the basis of its pharmacological effects.

Authors:  T Muramatsu
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 4.  Midkine in host defence.

Authors:  A Gela; S Jovic; S L Nordin; A Egesten
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

5.  Neointima formation in a restenosis model is suppressed in midkine-deficient mice.

Authors:  M Horiba; K Kadomatsu; E Nakamura; H Muramatsu; S Ikematsu; S Sakuma; K Hayashi; Y Yuzawa; S Matsuo; M Kuzuya; T Kaname; M Hirai; H Saito; T Muramatsu
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

6.  Chronic lung disease in preterm lambs: effect of daily vitamin A treatment on alveolarization.

Authors:  Kurt H Albertine; Mar Janna Dahl; Linda W Gonzales; Zheng-Ming Wang; Drew Metcalfe; Dallas M Hyde; Charles G Plopper; Barry C Starcher; David P Carlton; Richard D Bland
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-04-09       Impact factor: 5.464

Review 7.  Therapeutic potential of midkine in cardiovascular disease.

Authors:  Kenji Kadomatsu; Péter Bencsik; Anikó Görbe; Csaba Csonka; Kazuma Sakamoto; Satoshi Kishida; Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 8.  Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases.

Authors:  D R Jones
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

9.  Antisense oligonucleotide targeting midkine suppresses in vivo angiogenesis.

Authors:  Li-Cheng Dai; Xiang Wang; Xing Yao; Yong-Liang Lu; Jin-Liang Ping; Jian-Fang He
Journal:  World J Gastroenterol       Date:  2007-02-28       Impact factor: 5.742

Review 10.  The role of midkine in skeletal remodelling.

Authors:  A Liedert; T Schinke; A Ignatius; M Amling
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.